[Form 4] PTC Therapeutics, Inc. Insider Trading Activity
Rhea-AI Filing Summary
PTC Therapeutics insider transactions on 09/08/2025: Eric Pauwels, the company's Chief Business Officer and a director, executed a series of option exercises and contemporaneous sales under a Rule 10b5-1 plan adopted June 4, 2025. The filings show multiple option exercises at strike prices between $11.23 and $30.86 that resulted in acquisitions totaling 59,060 shares across several tranches. Simultaneously, Pauwels sold a total of 59,060 shares in multiple trades at weighted average sale prices in the mid-$56 range, reducing his reported beneficial ownership to 72,912 shares. Certain acquired shares include 272 shares from the employee stock purchase plan.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider exercised options and sold the resulting shares under a pre-established 10b5-1 plan, leaving meaningful retained ownership.
The filings indicate synchronized exercises and sales executed pursuant to a 10b5-1 plan, which typically aims to avoid timing-based trading claims. The activity increased reported gross acquisitions via exercises across multiple strikes ($11.23–$30.86) and generated proceeds via sales at weighted average prices around $56.6–$56.9. Net effect: reported beneficial ownership declined to 72,912 shares. For investors, this is a liquidity/harvesting event rather than an unplanned divestiture; materiality depends on context of total outstanding shares which is not provided in this filing.
TL;DR: Transactions were executed under a documented 10b5-1 plan and are disclosed with weighted-average prices and exercise details.
The report appropriately discloses exercise dates, strike prices, resulting share counts, and weighted-average sale prices. The filer includes explanatory notes about the 10b5-1 plan adoption date and aggregation of multi-trade sale prices. Signature by an attorney-in-fact is included. From a governance and disclosure perspective, the form meets standard SEC Form 4 transparency expectations; it does not provide any forward-looking information or rationale beyond compliance documentation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 16,698 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 6,017 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 8,528 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 3,713 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 2,406 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 1,238 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 1,250 | $0.00 | -- |
| Exercise | Common Stock | 16,698 | $30.86 | $515K |
| Sale | Common Stock | 16,698 | $56.94 | $951K |
| Exercise | Common Stock | 6,017 | $11.23 | $68K |
| Sale | Common Stock | 6,017 | $56.91 | $342K |
| Exercise | Common Stock | 8,528 | $18.01 | $154K |
| Sale | Common Stock | 8,528 | $56.92 | $485K |
| Exercise | Common Stock | 3,713 | $30.86 | $115K |
| Sale | Common Stock | 3,713 | $56.92 | $211K |
| Exercise | Common Stock | 2,406 | $11.23 | $27K |
| Sale | Common Stock | 2,406 | $56.92 | $137K |
| Exercise | Common Stock | 1,238 | $11.32 | $14K |
| Sale | Common Stock | 1,238 | $56.85 | $70K |
| Exercise | Common Stock | 1,250 | $11.32 | $14K |
| Sale | Common Stock | 1,250 | $56.86 | $71K |
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.59 to $57.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.60 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.57 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable.
